In rabbits, fetal weight reduction and cleft palate were observed at a fluticasone propionate dose approximately times the MRHDID for adults (on a mg/m² basis at a maternal subcutaneous dose of 4 mcg/kg/day). However, no teratogenic effects were reported at fluticasone propionate doses up to approximately 20 times the MRHDID for adults (on a mg/m² basis at a maternal oral dose up to 300 mcg/kg/day). No fluticasone propionate was detected in the plasma in this study, consistent with the established low bioavailability following oral administration [see CLINICAL PHARMACOLOGY ].
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.
Formulary status may vary and is subject to change. Please verify coverage and updated information on the website of your patient’s particular health plan or that of the Center for Medicare & Medicaid Services (CMS). Formulary coverage does not imply clinical efficacy or safety. GSK does not endorse individual plans. This information is not a guarantee of coverage or payment (partial or full). Actual benefits and out-of-pocket costs are determined by each plan administrator per its respective policies. Consumers are responsible for varying out-of-pocket costs based on the individual plan.